JP2020510016A - クローン病及び潰瘍性大腸炎を処置する方法 - Google Patents

クローン病及び潰瘍性大腸炎を処置する方法 Download PDF

Info

Publication number
JP2020510016A
JP2020510016A JP2019548450A JP2019548450A JP2020510016A JP 2020510016 A JP2020510016 A JP 2020510016A JP 2019548450 A JP2019548450 A JP 2019548450A JP 2019548450 A JP2019548450 A JP 2019548450A JP 2020510016 A JP2020510016 A JP 2020510016A
Authority
JP
Japan
Prior art keywords
patient
weeks
pharmaceutically acceptable
upadacitinib
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019548450A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020510016A5 (enExample
Inventor
タッカー，ルーパール・ビー
ジュンガーワース，スティーブン
マチャド・デ・ラセルダ，アナ・ポーラ
ロビンソン，アン・エム
エネホサ，ホセ・ジェフリー・ブイ
パンガン，アイリーン・エル
モハメッド，モハメッド−エスラーム
オスマン，アハメド
クリュンダー，ベン
アライアン，アイマン・ディー
ボーチャート，トーマス・ビー
ノルドストローム，フレドリック・ラース
シャイフ，アフマド・ワイ
マルハーン，マシュー・エム
ジャヤンス，ジャヤンシー
マローム，パトリック・ジェイ
メイヤー，ピーター・ティー
Original Assignee
アッヴィ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61750557&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2020510016(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by アッヴィ・インコーポレイテッド filed Critical アッヴィ・インコーポレイテッド
Publication of JP2020510016A publication Critical patent/JP2020510016A/ja
Publication of JP2020510016A5 publication Critical patent/JP2020510016A5/ja
Priority to JP2023177288A priority Critical patent/JP2024009963A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019548450A 2017-03-09 2018-03-09 クローン病及び潰瘍性大腸炎を処置する方法 Pending JP2020510016A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023177288A JP2024009963A (ja) 2017-03-09 2023-10-13 クローン病及び潰瘍性大腸炎を処置する方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762469337P 2017-03-09 2017-03-09
US62/469,337 2017-03-09
US201762470565P 2017-03-13 2017-03-13
US62/470,565 2017-03-13
US201762483289P 2017-04-07 2017-04-07
US62/483,289 2017-04-07
US201762593629P 2017-12-01 2017-12-01
US62/593,629 2017-12-01
PCT/US2018/021800 WO2018165581A1 (en) 2017-03-09 2018-03-09 Methods of treating crohn's disease and ulcerative colitis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023177288A Division JP2024009963A (ja) 2017-03-09 2023-10-13 クローン病及び潰瘍性大腸炎を処置する方法

Publications (2)

Publication Number Publication Date
JP2020510016A true JP2020510016A (ja) 2020-04-02
JP2020510016A5 JP2020510016A5 (enExample) 2021-04-22

Family

ID=61750557

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019548450A Pending JP2020510016A (ja) 2017-03-09 2018-03-09 クローン病及び潰瘍性大腸炎を処置する方法
JP2023177288A Pending JP2024009963A (ja) 2017-03-09 2023-10-13 クローン病及び潰瘍性大腸炎を処置する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023177288A Pending JP2024009963A (ja) 2017-03-09 2023-10-13 クローン病及び潰瘍性大腸炎を処置する方法

Country Status (9)

Country Link
US (3) US20190046527A1 (enExample)
EP (2) EP4487908A3 (enExample)
JP (2) JP2020510016A (enExample)
CN (2) CN120661512A (enExample)
AU (2) AU2018230500B2 (enExample)
BR (1) BR112019018576A2 (enExample)
MX (2) MX2019010733A (enExample)
TW (2) TWI851536B (enExample)
WO (2) WO2018165581A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024501051A (ja) * 2020-12-29 2024-01-10 アッヴィ・インコーポレイテッド 持続放出ウパダシチニブ配合物

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3251507A1 (en) 2015-10-16 2025-05-21 Abbvie Inc. Use of a solid dosage form comprising (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide for treating rheumatoid arthritis
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
WO2018165581A1 (en) * 2017-03-09 2018-09-13 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
US11564922B2 (en) 2017-03-09 2023-01-31 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
US20220002306A1 (en) * 2018-09-29 2022-01-06 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of upadacitinib and preparation method and use thereof
EP3891151A1 (en) * 2018-12-05 2021-10-13 LEK Pharmaceuticals d.d. Crystalline phosphate salt of selective jak1 inhibitor upadacitinib
CN111909160B (zh) * 2019-05-09 2024-05-28 苏州鹏旭医药科技有限公司 一种乌帕替尼盐类化合物及其制备方法
CN110101669A (zh) * 2019-06-11 2019-08-09 南京新酶合医药科技有限公司 一种乌帕替尼颗粒的生产工艺
BR112022005765A2 (pt) 2019-09-30 2022-06-21 Abbvie Inc Tratamento contra afecções espondiloartríticas e psoriáticas com upadacitinib
KR20230038229A (ko) 2020-07-08 2023-03-17 크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디. 우파다시티닙의 결정형, 이의 제조 방법 및 이의 용도
CN114380837B (zh) * 2021-12-27 2023-06-30 上海邈金医药科技有限公司 一种具有Janus激酶抑制活性的化合物、包括该化合物的组合物及其应用
AU2023206381A1 (en) * 2022-01-13 2024-07-25 Abbvie Inc. Method of administering upadacitinib to avoid adverse drug interactions and effects
EP4465971A1 (en) * 2022-01-20 2024-11-27 Renata Phramaceutical (Ireland) Limited Sustained release pharmaceutical composition of upadacitinib
WO2024052820A1 (en) * 2022-09-09 2024-03-14 Intas Pharmaceuticals Ltd. Upadacitinib formulation
US20240242807A1 (en) * 2023-01-17 2024-07-18 Children's Hospital Medical Center Model-informed precision dosing systems for treatment of inflammatory bowel disease
WO2025149974A1 (en) * 2024-01-11 2025-07-17 Takeda Pharmaceutical Company Limited Combination therapy with an anti-alpha4beta7 antibody
CN120699157B (zh) * 2025-07-16 2025-12-16 安康市中心医院 一种治疗溃疡性结肠炎的恢复肠屏障功能抗体及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448253B1 (en) 1998-09-16 2002-09-10 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor modulators
GB0115393D0 (en) 2001-06-23 2001-08-15 Aventis Pharma Ltd Chemical compounds
GB0124299D0 (en) 2001-10-10 2001-11-28 Astrazeneca Ab Crystal structure of enzyme and uses thereof
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
MXPA06013250A (es) 2004-05-14 2007-02-28 Abbott Lab Inhibidores de quinasa como agentes terapeuticos.
CN100381175C (zh) 2004-10-09 2008-04-16 山西中医学院 一种微乳制剂及其制备方法
CN101389630A (zh) 2005-12-29 2009-03-18 艾博特公司 蛋白激酶抑制剂
CA2665214A1 (en) 2006-10-06 2008-05-29 Abbott Laboratories Novel imidazothiazoles and imidazoxazoles
PT2152250T (pt) 2007-05-07 2019-12-12 Evonik Operations Gmbh Formas farmacêuticas sólidas que compreendem um revestimento entérico com libertação acelerada do fármaco
US8188083B2 (en) 2007-06-28 2012-05-29 Abbott Laboratories Triazolopyridazines
US20120276206A1 (en) 2008-03-28 2012-11-01 Boehringer Ingelheim International Gmbh Method for manufacturing acid pellets
KR20110017431A (ko) 2008-06-10 2011-02-21 아보트 러보러터리즈 신규한 트리사이클릭 화합물
CN101904814A (zh) 2009-06-04 2010-12-08 上海恒瑞医药有限公司 制备载药乳剂的方法
CA2769760A1 (en) 2009-07-31 2011-02-03 Ranbaxy Laboratories Limited Multi-layered, multiple unit pharmaceutical compositions
TWI500620B (zh) 2009-12-01 2015-09-21 Abbvie Inc 新穎三環化合物
FR2991171B1 (fr) 2012-06-01 2014-05-23 Galderma Res & Dev Procede de preparation d'une composition dermatologique comprenant des oleosomes
JP6041823B2 (ja) 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
CA2926361A1 (en) * 2013-10-24 2015-04-30 Abbvie Inc. Jak1 selective inhibitor and uses thereof
US20170266289A1 (en) 2014-08-27 2017-09-21 Abbvie Inc. Topical formulation
JP6796083B2 (ja) 2015-06-09 2020-12-02 カプスゲル・ベルギウム・ナムローゼ・フェンノートシャップＣａｐｓｕｇｅｌ Ｂｅｌｇｉｕｍ ＮＶ カプセル中の薬剤の噴霧乾燥ディスパーションからの迅速な溶解を達成するための製剤
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CA3251507A1 (en) 2015-10-16 2025-05-21 Abbvie Inc. Use of a solid dosage form comprising (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide for treating rheumatoid arthritis
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
EP4190318A1 (en) * 2016-12-14 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices
WO2018165581A1 (en) 2017-03-09 2018-09-13 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"874h - Safety and Efficacy of ABT-494 (Upadacitinib), an Oral Jak1 Inhibitor, as Induction Therapy i", GASTROENTEROLOGY, vol. Vol.152, No.5, Supplement 1, JPN7022004919, 22 April 2017 (2017-04-22), pages 1308 - 1309, ISSN: 0004904138 *
"History of Changes for Study: NCT02365649", CLINICALTRIALS.GOV ARCHIVE [ONLINE], JPN6022044110, 26 January 2017 (2017-01-26), ISSN: 0005081918 *
"History of Changes for Study: NCT02782663", CLINICALTRIALS.GOV ARCHIVE [ONLINE], JPN6022044111, 24 February 2017 (2017-02-24), ISSN: 0004904136 *
"History of Changes for Study: NCT02819635", CLINICALTRIALS.GOV ARCHIVE [ONLINE], JPN6022044113, 13 January 2017 (2017-01-13), ISSN: 0004904134 *
"History of Changes for Study: NCT03006068", CLINICALTRIALS.GOV ARCHIVE [ONLINE], JPN6022044117, 7 March 2017 (2017-03-07), ISSN: 0004904137 *
CLINICAL PHARMACOKINETICS, vol. 55, no. 12, JPN6022005045, 2016, pages 1547 - 1558, ISSN: 0005081917 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024501051A (ja) * 2020-12-29 2024-01-10 アッヴィ・インコーポレイテッド 持続放出ウパダシチニブ配合物

Also Published As

Publication number Publication date
US20210361647A1 (en) 2021-11-25
CN110392572A (zh) 2019-10-29
EP4487908A2 (en) 2025-01-08
US11607411B2 (en) 2023-03-21
US20190046527A1 (en) 2019-02-14
AU2024203642B2 (en) 2025-08-21
BR112019018576A2 (pt) 2020-04-14
CA3052873A1 (en) 2018-09-13
AU2018230500A1 (en) 2019-09-19
CN120661512A (zh) 2025-09-19
AU2018230500B2 (en) 2024-03-07
TW202517269A (zh) 2025-05-01
JP2024009963A (ja) 2024-01-23
TW201840318A (zh) 2018-11-16
MX2019010733A (es) 2019-11-01
EP4487908A3 (en) 2025-01-15
WO2018165581A1 (en) 2018-09-13
US20220233527A1 (en) 2022-07-28
MX2022015499A (es) 2023-01-24
EP3592353A1 (en) 2020-01-15
TWI851536B (zh) 2024-08-11
WO2022178492A1 (en) 2022-08-25
AU2024203642A1 (en) 2024-06-20

Similar Documents

Publication Publication Date Title
JP2024009963A (ja) クローン病及び潰瘍性大腸炎を処置する方法
US10730883B2 (en) Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11976077B2 (en) Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms therof
US11564922B2 (en) Methods of treating crohn's disease and ulcerative colitis
HK40123037A (en) Methods of treating crohn's disease and ulcerative colitis
CA3052873C (en) Use of upadacitinib to treat crohn's disease and ulcerative colitis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210308

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210308

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220808

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221025

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230425

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230613